12/22
09:02 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.
12/16
08:43 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/15
01:12 pm
kymr
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. [Yahoo! Finance]
Low
Report
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. [Yahoo! Finance]
12/11
04:01 pm
kymr
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/11
09:57 am
kymr
Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]
Low
Report
Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]
12/11
08:06 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.
12/11
08:05 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $120.00 price target on by analysts at Mizuho.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $120.00 price target on by analysts at Mizuho.
12/11
07:31 am
kymr
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis [Yahoo! Finance]
12/11
07:00 am
kymr
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
Low
Report
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
12/10
11:04 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $125.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at JPMorgan Chase & Co. from $70.00 to $125.00. They now have an "overweight" rating on the stock.
12/10
12:10 am
kymr
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering [Yahoo! Finance]
12/9
11:30 pm
kymr
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
Low
Report
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
12/9
03:05 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/9
10:04 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $116.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $116.00 price target on by analysts at Truist Financial Corporation.
12/9
09:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/9
09:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/9
09:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/9
08:46 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/9
08:11 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
12/9
08:07 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at Bank of America Corporation from $71.00 to $112.00. They now have a "buy" rating on the stock.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at Bank of America Corporation from $71.00 to $112.00. They now have a "buy" rating on the stock.
12/9
07:21 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/9
07:01 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/9
06:06 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/8
07:00 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $118.00 price target on by analysts at Leerink Partners.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $118.00 price target on by analysts at Leerink Partners.
12/8
06:06 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $138.00 price target on by analysts at BTIG Research.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $138.00 price target on by analysts at BTIG Research.